Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accumulated Depreciation: 2020-2025

Historic Accumulated Depreciation for SAB Biotherapeutics (SABS) over the last 3 years, with Sep 2025 value amounting to $16.8 million.

  • SAB Biotherapeutics' Accumulated Depreciation rose 21.46% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 21.46%. This contributed to the annual value of $14.6 million for FY2024, which is 47.04% up from last year.
  • SAB Biotherapeutics' Accumulated Depreciation amounted to $16.8 million in Q3 2025, which was up 4.63% from $16.1 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Accumulated Depreciation ranged from a high of $16.8 million in Q3 2025 and a low of $3.2 million during Q4 2021.
  • For the 3-year period, SAB Biotherapeutics' Accumulated Depreciation averaged around $13.4 million, with its median value being $13.8 million (2024).
  • Data for SAB Biotherapeutics' Accumulated Depreciation shows a peak YoY soared of 94.98% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Accumulated Depreciation stood at $3.2 million in 2021, then skyrocketed by 94.98% to $6.3 million in 2022, then surged by 57.87% to $9.9 million in 2023, then soared by 47.04% to $14.6 million in 2024, then rose by 21.46% to $16.8 million in 2025.
  • Its last three reported values are $16.8 million in Q3 2025, $16.1 million for Q2 2025, and $15.3 million during Q1 2025.